Skip to main content

Prokidney Corp.

PROK
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001850270

In the last 90 days, Prokidney Corp. insiders filed 0 open-market purchases and 1 sale; 71 institutions reported holding it in 13F filings for Q2 2026, worth $99.5M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Prokidney Corp. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of PROK: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders56560
Shares35.2M34.5M−763.4K (−2.2%)
Value$20.9M$83.4M+$62.5M (+299.9%)

New holders (17)

Institutions that held Prokidney Corp. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to PROK in Q3 2025
InstitutionSharesValue% of portfolio
Millennium Management LLC1,956,378$4.73M0.00%
MYDA Advisors LLC450,000$1.09M0.33%
Citadel Advisors LLC344,789$834.4K0.00%
Squarepoint Ops LLC344,576$833.9K0.00%
Susquehanna Portfolio Strategies, LLC143,462$347.2K0.01%
Virtu Financial LLC84,002$203.0K0.01%
Simplex Trading, LLC77,818$188.0K0.00%
Jefferies Financial Group Inc.65,300$158.0K0.00%
Letko, Brosseau & Associates Inc15,900$38.5K0.00%
Zullo Investment Group, Inc.11,620$28.1K0.01%
Engineers Gate Manager LP10,452$25.3K0.00%
Groupe la Francaise1,500$3.17K0.00%
Caitlin John, LLC350$8470.00%
SRS Capital Advisors, Inc.248$6000.00%
Advisory Services Network, LLC184$4450.00%
Signaturefd, LLC150$3640.00%
Rockefeller Capital Management L.P.12$290.00%

Sold out (17)

Institutions that held Prokidney Corp. at the end of Q2 2025 and filed for Q3 2025 without it.